Wealth Enhancement Advisory Services LLC Purchases 15,214 Shares of Coherus Oncology, Inc. (NASDAQ:CHRS)

Wealth Enhancement Advisory Services LLC lifted its stake in Coherus Oncology, Inc. (NASDAQ:CHRS) by 97.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,847 shares of the biotechnology company’s stock after buying an additional 15,214 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Coherus Oncology were worth $43,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Coherus Oncology by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 976,857 shares of the biotechnology company’s stock worth $1,348,000 after buying an additional 12,530 shares during the period. Wells Fargo & Company MN raised its stake in shares of Coherus Oncology by 32.4% in the fourth quarter. Wells Fargo & Company MN now owns 61,830 shares of the biotechnology company’s stock worth $85,000 after buying an additional 15,137 shares during the period. Bank of Montreal Can bought a new position in shares of Coherus Oncology in the fourth quarter worth about $34,000. Intech Investment Management LLC bought a new position in shares of Coherus Oncology in the fourth quarter worth about $38,000. Finally, Geode Capital Management LLC raised its stake in shares of Coherus Oncology by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 2,599,639 shares of the biotechnology company’s stock worth $3,588,000 after buying an additional 34,494 shares during the period. Institutional investors own 72.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. UBS Group reaffirmed a “neutral” rating and issued a $1.05 price objective (down previously from $1.50) on shares of Coherus Oncology in a research note on Thursday, April 24th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Coherus Oncology in a research report on Tuesday, April 29th. Finally, Wall Street Zen cut Coherus Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, May 20th.

Coherus Oncology Trading Up 1.3%

NASDAQ:CHRS opened at $0.77 on Thursday. Coherus Oncology, Inc. has a 12-month low of $0.66 and a 12-month high of $2.43. The stock has a 50-day moving average price of $0.89 and a 200 day moving average price of $1.11. The stock has a market capitalization of $88.99 million, a P/E ratio of -0.68 and a beta of 0.88.

Coherus Oncology (NASDAQ:CHRS) last released its earnings results on Monday, May 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.04). The company had revenue of $7.60 million during the quarter, compared to analysts’ expectations of $59.79 million. During the same period in the prior year, the company earned ($0.32) EPS. On average, research analysts predict that Coherus Oncology, Inc. will post -1.05 earnings per share for the current fiscal year.

Insider Buying and Selling at Coherus Oncology

In other Coherus Oncology news, Director Mats Wahlstrom sold 99,988 shares of the firm’s stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $0.74, for a total transaction of $73,991.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 8.08% of the stock is currently owned by company insiders.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.